Minerva Neurosciences, Inc. (NERV) Stock Price & Analysis
Minerva Neurosciences, Inc. (NERV) rose 2.38% to USD 4.74 as of June 10, 2026 at 04:22 UTC, according to Nexqual real-time market data.
NERV last closed at USD 4.63; the session ranged USD 4.57–4.87 on volume of 96,303 shares. Market capitalization is $220.83M, with a 52-week range of USD 1.57–12.46 (NCM). Source: Nexqual, June 10, 2026 at 04:22 UTC.
Key Statistics (as of June 10, 2026 at 04:22 UTC)
| Price | USD 4.74 |
|---|---|
| Change | ▲ 2.38% (up) |
| Previous Close | USD 4.63 |
| Open | USD 4.67 |
| Day Range | USD 4.57 – 4.87 |
| 52-Week Range | USD 1.57 – 12.46 |
| Volume | 96,303 shares |
| Market Cap | $220.83M |
| Exchange | NCM |
Technical Analysis (NERV)
Nexqual's technical model rates NERV "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 04:22 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 33.25 (neutral) |
| vs SMA50 | Below (USD 5.71) |
| MACD | -0.32 (negative) |
Analyst Ratings (NERV)
Wall Street analysts rate NERV "Hold" based on 3 analysts, with a mean price target of USD 9.5 (range USD 7–14), per Nexqual as of June 10, 2026 at 04:22 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 9.5 |
| High Target | USD 14 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 1 / 2 / 0 |
Earnings (NERV)
| EPS Estimate | USD -0.01 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.17 vs est -0.13 ▼ miss |
| 2025-12-31 | USD -0.64 vs est -0.11 ▼ miss |
| 2025-06-30 | USD -0.43 vs est -0.9 ▲ beat |
Source: Nexqual, June 10, 2026 at 04:22 UTC.
Financials & Fundamentals (NERV)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 17.65 |
| Total Cash | $78.06M |
| Total Debt | $60.00M |
| Free Cash Flow | $-5.55M |
Source: Nexqual, June 10, 2026 at 04:22 UTC.
Financial Health Score (NERV)
Nexqual rates Minerva Neurosciences, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 04:22 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $78M cash vs $60M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$15M |
| Efficiency | Mixed — No data |
Ownership (NERV)
| Insider Ownership | +3.34% |
|---|---|
| Institutional Ownership | +89.53% |
| Shares Outstanding | 46.59M |
| Float | 30.87M |
| Short % of Float | +2.21% |
Source: Nexqual, June 10, 2026 at 04:22 UTC.
Leadership (NERV)
Minerva Neurosciences, Inc. is led by Remy Luthringer (age 64), Executive Chairman, CEO & Member of Scientific Advisory Board, per Nexqual as of June 10, 2026 at 04:22 UTC.
| Executive Chairman, CEO & Member of Scientific Advisory Board | Remy Luthringer (age 64) |
|---|---|
| Senior VP, CFO & Secretary | Frederick W. Ahlholm (age 59) |
| Senior VP & COO | Joseph Reilly (age 50) |
| Vice President of Investor Relations & Corporate Communications | William B. Boni (age 73) |
Major Backers & Investors (NERV)
Notable institutional backers of Minerva Neurosciences, Inc. include Federated Hermes, Inc., Vivo Capital, LLC, Janus Henderson Group PLC, according to Nexqual as of June 10, 2026 at 04:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Federated Hermes, Inc. | 22.94% |
| Vivo Capital, LLC | 9.28% |
| Janus Henderson Group PLC | 9.22% |
| Balyasny Asset Management LP | 9.14% |
| Logos Global Management LP | 6.9% |
| Farallon Capital Management LLC | 5.08% |
| Foresite Capital Management VI LLC | 4.26% |
| Spruce Street Capital LP | 3.55% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.88% |
Source: Nexqual, June 10, 2026 at 04:22 UTC.
From Minerva Neurosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-11)
Key Strengths & Strategy (as disclosed to the SEC)
- Moreover, the filing of an application for regulatory approval, including an NDA, or Biologics License Application ("BLA"), a Marketing Authorization Application ("MAA") in the EEA, or comparable foreign regulatory applications for approval, requires a payment of a significant user fee upon submission.
- Our product candidates and the activities associated with their development and commercialization in the United States, including, but not limited to, their advertising and promotion, will further be heavily scrutinized by the FDA, the United States Department of Justice, the United States Department of Health and Human Services' ("HHS's") Office of Inspector General, state attorneys general, 34 members of Congress and the public.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KALA | KALA BIO, Inc. | USD 2.35 | ▲ 14.08% |
| CTMX | CytomX Therapeutics, Inc. | USD 2.98 | ▼ 0.67% |
| CRVS | Corvus Pharmaceuticals, Inc. | USD 11.17 | ▲ 0.45% |
| ATXI | Avenue Therapeutics, Inc. | USD 0.36 | ▲ 2.27% |
| ALDX | Aldeyra Therapeutics, Inc. | USD 1.72 | ▲ 5.52% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:22 UTC. This page is informational and not investment advice.